Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conv...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2020-09, Vol.12 (10), p.937
Main Authors: Pothin, Elodie, Lesuisse, Dominique, Lafaye, Pierre
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Biotechnology
blood–brain barrier (BBB)
drug delivery
Insulin
Insulin-like growth factors
Life Sciences
Molecular weight
Proteins
Review
single-domain antibody
variable domain of heavy-chain antibody (VHH)
variable new antigen receptor (VNAR)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73
cites cdi_FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73
container_end_page
container_issue 10
container_start_page 937
container_title Pharmaceutics
container_volume 12
creator Pothin, Elodie
Lesuisse, Dominique
Lafaye, Pierre
description Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood-brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.
doi_str_mv 10.3390/pharmaceutics12100937
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5926b14a6803488c98a8b0fb50ea8de4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5926b14a6803488c98a8b0fb50ea8de4</doaj_id><sourcerecordid>2550236579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73</originalsourceid><addsrcrecordid>eNptUk1r3DAUFKWlCWl-Qouhl17cPlkflnoouJsmG1ha6EeuQpblXS22tJHshfz7Ktk0JKHvIqE3M3pvGITeYvhIiIRPu42OozZ2npxJuMIAktQv0DGWUpZUVuTlo_sROk1pC7kIwYLI1-iIEIBaAj1Gi69RO1-c2cHtbbwpQl_8cn492PIsjLedxk-uDZ2z6XPRFOfBzKkIvrhaLgvtu-Lqe_PzDXrV6yHZ0_vzBP05__Z7sSxXPy4uF82qNIySqaw6hitGpeFMCialwIyz1so8v6hbIqigXd0BtGAZ76hmpu0hA4ymBvO-Jifo8qDbBb1Vu-hGHW9U0E7dPYS4VjpmRwarmKx4i6nmAggVwkihRQt9y8Bq0Vmatb4ctHZzO9rOWD9FPTwRfdrxbqPWYa9qDpjUJAuUB4HNM9qyWamdTpOdowLCss-U7nHGf7j_MIbr2aZJjS4ZOwza2zAnVdG8P_BcGfr-GXQb5uiztapiDCrCWS0zih1QJoaUou0fpsCgblOi_puSzHv3ePMH1r9MkL9q9rhV</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2550236579</pqid></control><display><type>article</type><title>Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content (ProQuest)</source><creator>Pothin, Elodie ; Lesuisse, Dominique ; Lafaye, Pierre</creator><creatorcontrib>Pothin, Elodie ; Lesuisse, Dominique ; Lafaye, Pierre</creatorcontrib><description>Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood-brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics12100937</identifier><identifier>PMID: 33007904</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antigens ; Biotechnology ; blood–brain barrier (BBB) ; drug delivery ; Insulin ; Insulin-like growth factors ; Life Sciences ; Molecular weight ; Proteins ; Review ; single-domain antibody ; variable domain of heavy-chain antibody (VHH) ; variable new antigen receptor (VNAR)</subject><ispartof>Pharmaceutics, 2020-09, Vol.12 (10), p.937</ispartof><rights>2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73</citedby><cites>FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73</cites><orcidid>0000-0002-5761-1342</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2550236579/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2550236579?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,75096</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33007904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://pasteur.hal.science/pasteur-03507944$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pothin, Elodie</creatorcontrib><creatorcontrib>Lesuisse, Dominique</creatorcontrib><creatorcontrib>Lafaye, Pierre</creatorcontrib><title>Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR</title><title>Pharmaceutics</title><addtitle>Pharmaceutics</addtitle><description>Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood-brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Biotechnology</subject><subject>blood–brain barrier (BBB)</subject><subject>drug delivery</subject><subject>Insulin</subject><subject>Insulin-like growth factors</subject><subject>Life Sciences</subject><subject>Molecular weight</subject><subject>Proteins</subject><subject>Review</subject><subject>single-domain antibody</subject><subject>variable domain of heavy-chain antibody (VHH)</subject><subject>variable new antigen receptor (VNAR)</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1r3DAUFKWlCWl-Qouhl17cPlkflnoouJsmG1ha6EeuQpblXS22tJHshfz7Ktk0JKHvIqE3M3pvGITeYvhIiIRPu42OozZ2npxJuMIAktQv0DGWUpZUVuTlo_sROk1pC7kIwYLI1-iIEIBaAj1Gi69RO1-c2cHtbbwpQl_8cn492PIsjLedxk-uDZ2z6XPRFOfBzKkIvrhaLgvtu-Lqe_PzDXrV6yHZ0_vzBP05__Z7sSxXPy4uF82qNIySqaw6hitGpeFMCialwIyz1so8v6hbIqigXd0BtGAZ76hmpu0hA4ymBvO-Jifo8qDbBb1Vu-hGHW9U0E7dPYS4VjpmRwarmKx4i6nmAggVwkihRQt9y8Bq0Vmatb4ctHZzO9rOWD9FPTwRfdrxbqPWYa9qDpjUJAuUB4HNM9qyWamdTpOdowLCss-U7nHGf7j_MIbr2aZJjS4ZOwza2zAnVdG8P_BcGfr-GXQb5uiztapiDCrCWS0zih1QJoaUou0fpsCgblOi_puSzHv3ePMH1r9MkL9q9rhV</recordid><startdate>20200930</startdate><enddate>20200930</enddate><creator>Pothin, Elodie</creator><creator>Lesuisse, Dominique</creator><creator>Lafaye, Pierre</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5761-1342</orcidid></search><sort><creationdate>20200930</creationdate><title>Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR</title><author>Pothin, Elodie ; Lesuisse, Dominique ; Lafaye, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Biotechnology</topic><topic>blood–brain barrier (BBB)</topic><topic>drug delivery</topic><topic>Insulin</topic><topic>Insulin-like growth factors</topic><topic>Life Sciences</topic><topic>Molecular weight</topic><topic>Proteins</topic><topic>Review</topic><topic>single-domain antibody</topic><topic>variable domain of heavy-chain antibody (VHH)</topic><topic>variable new antigen receptor (VNAR)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pothin, Elodie</creatorcontrib><creatorcontrib>Lesuisse, Dominique</creatorcontrib><creatorcontrib>Lafaye, Pierre</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pothin, Elodie</au><au>Lesuisse, Dominique</au><au>Lafaye, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR</atitle><jtitle>Pharmaceutics</jtitle><addtitle>Pharmaceutics</addtitle><date>2020-09-30</date><risdate>2020</risdate><volume>12</volume><issue>10</issue><spage>937</spage><pages>937-</pages><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood-brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33007904</pmid><doi>10.3390/pharmaceutics12100937</doi><orcidid>https://orcid.org/0000-0002-5761-1342</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1999-4923
ispartof Pharmaceutics, 2020-09, Vol.12 (10), p.937
issn 1999-4923
1999-4923
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5926b14a6803488c98a8b0fb50ea8de4
source PubMed Central (Open Access); Publicly Available Content (ProQuest)
subjects Antibodies
Antigens
Biotechnology
blood–brain barrier (BBB)
drug delivery
Insulin
Insulin-like growth factors
Life Sciences
Molecular weight
Proteins
Review
single-domain antibody
variable domain of heavy-chain antibody (VHH)
variable new antigen receptor (VNAR)
title Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T23%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brain%20Delivery%20of%20Single-Domain%20Antibodies:%20A%20Focus%20on%20VHH%20and%20VNAR&rft.jtitle=Pharmaceutics&rft.au=Pothin,%20Elodie&rft.date=2020-09-30&rft.volume=12&rft.issue=10&rft.spage=937&rft.pages=937-&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics12100937&rft_dat=%3Cproquest_doaj_%3E2550236579%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c543t-2d512549c659859981565be912187b38484d7d00b0e56d4a5cbf05beca4c16f73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2550236579&rft_id=info:pmid/33007904&rfr_iscdi=true